Aug 3, 2026 08:00AM
Aug 3, 2026 08:00AM
Jun 22, 2026 08:30AM
Apr 6, 2026 08:00AM
Feb 4, 2026 08:32AM
Feb 4, 2026 08:30AM
May 6, 2025 04:01PM Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
Apr 17, 2025 07:01AM
Apr 17, 2025 07:00AM
May 28, 2024 08:45AM
May 28, 2024 08:45AM
May 14, 2024 08:30AM
May 13, 2024 04:01PM
May 2, 2024 09:15AM Aprea Therapeutics (APRE) Appoints Nadeem Q. Mirza as Chief Medical Officer
May 2, 2024 09:15AM
Apr 10, 2024 12:00PM
Mar 26, 2024 07:45AM
Mar 11, 2024 08:30AM
Mar 11, 2024 08:30AM
Mar 11, 2024 08:29AM
Mar 11, 2024 08:29AM Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
Feb 6, 2024 08:01AM
Feb 6, 2024 08:01AM
Jan 30, 2024 08:00AM
Jan 4, 2024 04:06PM
Jan 4, 2024 04:05PM
Nov 9, 2023 04:05PM
Mar 30, 2023 04:05PM Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
Mar 30, 2023 04:05PM
Aug 11, 2022 04:15PM
Aug 11, 2022 04:15PM
Mar 15, 2022 04:15PM
Mar 15, 2022 04:15PM
Jan 6, 2022 08:00AM
Dec 14, 2021 08:00AM Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hemat
Dec 14, 2021 08:00AM
Dec 13, 2021 08:00AM
Dec 13, 2021 08:00AM
Dec 13, 2021 08:00AM
Dec 9, 2021 08:00AM
Dec 9, 2021 08:00AM
Dec 9, 2021 08:00AM Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies
Nov 8, 2021 04:15PM
Nov 8, 2021 04:15PM
Nov 4, 2021 04:15PM
Nov 4, 2021 04:15PM
Sep 21, 2021 09:21AM
Sep 20, 2021 06:47PM
Sep 20, 2021 04:15PM Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021
Sep 20, 2021 04:15PM

327,748 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All